A Single Arm, Open-Label, Phase 2 Trial Investigating Nitric Oxide-Inhalation (NO) in Nontuberculous Mycobacteria (NTM) Patients with Mycobacterium Abscessus Complex (MABSC)

Trial Profile

A Single Arm, Open-Label, Phase 2 Trial Investigating Nitric Oxide-Inhalation (NO) in Nontuberculous Mycobacteria (NTM) Patients with Mycobacterium Abscessus Complex (MABSC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Mycobacterium avium complex infections
  • Focus Adverse reactions
  • Acronyms NO-NTM Abscessus
  • Most Recent Events

    • 10 Aug 2017 New trial record
    • 07 Aug 2017 According to an AIT Therapeutics Inc media release, the first patient in this trial has been dosed.
    • 07 Aug 2017 According to an AIT Therapeutics Inc media release, Lea Bentur, M.D (Professor of Cystic Fibrosis and Pediatric Pulmonology and Director of the Pediatric Pulmonary unit at the Rambam Medical Center in Israel) and Ori Efrati, M.D (Professor of Cystic Fibrosis and Pediatric Pulmonology and the Head of the Pediatric Pulmonology Unit at the Safra Children Hospital in Tel Hashomer, Israel) are principal investigators of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top